Company news from the 05/22/07 news brief

Share this article:
Pfizer CEO Jeffrey Kindler has announced top-level leadership changes for the drugmaker’s research and finance functions. Pfizer said its longtime head of R&D John LaMattina will retire shortly after the company finds a replacement for him. LaMattina has been at Pfizer since 1977. Martin Mackay, currently VP R&D and head of worldwide development is said to be a contender to replace LaMattina. But Kindler, a former McDonald’s executive who got the Pfizer CEO job in part because he was a pharma outsider, may also look outside Pfizer to fill the post. Additionally, Alan Levin, the company’s CFO, will also step down as Pfizer looks to bring in a finance chief with more visibility and experience on Wall Street. Kindler’s background may also predispose him to look outside the pharmaceutical industry for Levin’s successor. Levin was the lieutenant to previous CFO David Shedlarz and took over as chief of finance in 2005. “With a strong finance organization in place, and after 20 years of service with Pfizer, I feel that now is the appropriate time for me to explore career opportunities outside of the company,” Levin said in a statement.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...